Reviva Pharmaceuticals Holdings, Inc.: 10-Q filed 2021-11-15
What Reviva Pharmaceuticals Holdings, Inc. reported in its quarterly report filed 2021-11-15 (fiscal Q3 2021): 24 published measures, 71 facts as tagged in accession 0001437749-21-026621.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-11-15
- Fiscal period
- fiscal Q3 2021
- Accession
- 0001437749-21-026621 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Reviva Pharmaceuticals Holdings, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 33,893,932 | USD | |
| At 2020-12-31 | 8,762,278 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 1,624,586 | USD | |
| At 2020-12-31 | 3,296,528 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 32,269,346 | USD | |
| At 2021-06-30 | 34,520,972 | USD | |
| At 2020-12-31 | 5,465,750 | USD | |
| At 2020-09-30 | -8,646,813 | USD | |
| At 2020-06-30 | -8,411,825 | USD | |
| At 2019-12-31 | -6,811,430 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 33,491,616 | USD | |
| At 2020-12-31 | 8,760,462 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -2,279,216 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -4,836,923 | USD | 273 |
| 2020-07-01 to 2020-09-30 | -659,088 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -2,259,483 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | -6,766,309 | USD | 273 |
| 2020-01-01 to 2020-09-30 | -1,131,035 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 31,497,463 | USD | 273 |
| 2020-01-01 to 2020-09-30 | 1,484,100 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | -63,147,016 | USD | |
| At 2020-12-31 | -58,310,093 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 2,102 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 6,004 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 547 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 1,347 | USD | 274 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 44,679 | USD | 273 |
| 2020-01-01 to 2020-09-30 | 0 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -2,476,840 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -6,139,870 | USD | 273 |
| 2020-07-01 to 2020-09-30 | -512,291 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -1,907,953 | USD | 274 |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 0 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 0 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 146,250 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 375,187 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 973,700 | USD | |
| At 2020-12-31 | 1,332,743 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 420,783 | USD | |
| At 2020-12-31 | 1,008,046 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 2,476,840 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 6,139,870 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 512,291 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 1,907,953 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 1,423,359 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 2,188,849 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 955 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 295,150 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 13,388,986 | shares | |
| At 2020-12-31 | 9,231,737 | shares | |
| At 2020-12-14 | 9,231,737 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 95,415,024 | USD | |
| At 2020-12-31 | 63,774,920 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 402,316 | USD | |
| At 2020-12-31 | 1,816 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -2,277,114 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -4,830,919 | USD | 273 |
| 2020-07-01 to 2020-09-30 | -658,541 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -2,258,136 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 1,053,481 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 3,951,021 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 511,336 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 1,612,803 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 0 | USD | 273 |
| 2020-01-01 to 2020-09-30 | 484 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 199,726 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 1,308,951 | USD | 273 |
| 2020-07-01 to 2020-09-30 | -146,250 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -350,183 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | -587,263 | USD | 273 |
| 2020-01-01 to 2020-09-30 | 1,236,556 | USD | 274 |
Inspect the source
- Entity
- Reviva Pharmaceuticals Holdings, Inc. / CIK 0001742927
- Captured
- 2026-09-19T11:20:56.685Z
- SEC response SHA-256
26f740ff1a169faebcba46f28197dc15a1be7bab2feb9b4952e7b7f15df066e6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001742927.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))